Global Ankylosing Spondylitis Market Outlook Report 2019-2027: Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities
Dublin, Dec. 21, 2020 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
Global Ankylosing Spondylitis market accounted for $4.38 billion in 2019 and is expected to reach $9.59 billion by 2027 growing at a CAGR of 10.3% during the forecast period.
Rising prevalence of Ankylosing Spondylitis, growing awareness about diagnostics and treatments for the disease. Additionally, government initiatives and getting better healthcare infrastructure are the major factors propelling the market growth. However, the huge cost of treatment and lack of skilled surgeons and physiotherapists are hampering the market growth.
Ankylosing spondylitis is a chronic inflammatory disease that affects the spine. It is a kind of arthritis, in which spine bones grow or fuse together, causing the spine to turn into rigid. Symptoms of ankylosing spondylitis comprise pain and stiffness from the neck to the lower back, bony fusion, and pain in the ligaments and tendons. These symptomatic changes may be mild or severe, and may lead to a stooped-over posture.
Based on the drugs, the humira segment is going to have a lucrative growth during the forecast period due to it's a prescription medicine used to reduce the signs and symptoms of ankylosing spondylitis in adults. Humira can help to reduce the back pain, stiffness of AS, low cost and high efficiency.
By geography, North America is going to have a lucrative growth during the forecast period due to the more prevalence of the disease and amplified adoption of ankylosing spondylitis treatment options in the region. In addition, technological developments are driving ankylosing spondylitis treatment in this region.
Some of the key players profiled in the Ankylosing Spondylitis Market include Abbvie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eisai, Eli Lilly and Company, F. Hoffmann-La Roche, Janssen Pharmaceuticals, Johnson & Johnson Services, Inc, Merck & Co, Novartis AG, Pfizer, Regeneron Pharmaceuticals, Sanofi, Shanghai Pharmaceuticals and UCB, Inc.
What the report offers:
Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2018, 2019 2020, 2024, and 2027
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends Company Profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements
Molecule Types Covered:
Biologics
Biosimilars
Small Molecules
Route of Administrations Covered:
Oral
Parenteral
Dosage Forms Covered:
Liquid
Solid
Drugs Covered:
Cimzia
Cosentyx
Enbrel
Humira
Remicade
Simponi
Drug Types Covered:
Anti-Inflammatory Drugs
COX Inhibitors
Disease-Modifying Anitrheumatic Drugs (DMARDs)
Immunosuppressive Drugs
JAK Inhibitors
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Steroids
TNF Inhibitors
IL-17 Inhibitors
Treatment Types Covered:
Medication
Surgery
Therapy
Applications Covered:
Adults
Juveniles
End Users Covered:
Hospital
Care Home
Clinic
Regions Covered:
North America
US
Canada
Mexico
Europe
Germany
UK
Italy
France
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
South America
Argentina
Brazil
Chile
Rest of South America
Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/mkp72o
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900